BR112017019776A2 - proteínas de fusão que compreendem glicoproteínas de superfície de alfavírus modificadas e antígeno associado a tumor e métodos dos mesmos - Google Patents

proteínas de fusão que compreendem glicoproteínas de superfície de alfavírus modificadas e antígeno associado a tumor e métodos dos mesmos

Info

Publication number
BR112017019776A2
BR112017019776A2 BR112017019776-6A BR112017019776A BR112017019776A2 BR 112017019776 A2 BR112017019776 A2 BR 112017019776A2 BR 112017019776 A BR112017019776 A BR 112017019776A BR 112017019776 A2 BR112017019776 A2 BR 112017019776A2
Authority
BR
Brazil
Prior art keywords
fusion proteins
surface glycoproteins
modified alphavirus
methods
alphavirus surface
Prior art date
Application number
BR112017019776-6A
Other languages
English (en)
Other versions
BR112017019776B1 (pt
Inventor
Leonardi Peter
Martina Pola Elin
Babad Jeffrey
Original Assignee
Omnicyte
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omnicyte filed Critical Omnicyte
Publication of BR112017019776A2 publication Critical patent/BR112017019776A2/pt
Publication of BR112017019776B1 publication Critical patent/BR112017019776B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente revelação se refere a proteínas de fusão que compreendem uma ou mais glicoproteínas de superfície de alfavírus modificadas e um ou mais antígenos específicos de tumor. também são reveladas proteínas de fusão que compreendem uma ou mais glicoproteínas de superfície de alfavírus modificadas e um ou mais antígenos específicos virais. também são reveladas proteínas de fusão que compreendem uma ou mais glicoproteínas de superfície de alfavírus modificadas. também se refere a métodos para ativar o sistema imunológico em pacientes de câncer para infiltrar e exterminar células tumorais ou células infectadas com um vírus latente. a presente revelação fornece uma tecnologia de plataforma que suscita uma resposta imunológica mais rápida, mais ampla e mais forte com o uso das proteínas de fusão.
BR112017019776-6A 2015-03-18 2016-03-18 proteínas de fusão que compreendem glicoproteínas de superfície de alfavírus modificadas e antígeno associado a tumor e métodos dos mesmos BR112017019776B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562134933P 2015-03-18 2015-03-18
US62/134,933 2015-03-18
PCT/US2016/023203 WO2016149643A2 (en) 2015-03-18 2016-03-18 Fusion proteins comprising modified alpha virus surface glycoproteins and tumor associated antigen and methods thereof

Publications (2)

Publication Number Publication Date
BR112017019776A2 true BR112017019776A2 (pt) 2018-05-22
BR112017019776B1 BR112017019776B1 (pt) 2020-07-28

Family

ID=56919485

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017019776-6A BR112017019776B1 (pt) 2015-03-18 2016-03-18 proteínas de fusão que compreendem glicoproteínas de superfície de alfavírus modificadas e antígeno associado a tumor e métodos dos mesmos

Country Status (12)

Country Link
US (3) US10660948B2 (pt)
EP (1) EP3270958A4 (pt)
JP (1) JP6921053B2 (pt)
KR (1) KR20170121301A (pt)
CN (2) CN114262380A (pt)
AU (2) AU2016232771B2 (pt)
BR (1) BR112017019776B1 (pt)
CA (1) CA2979697A1 (pt)
HK (1) HK1248610A1 (pt)
MX (1) MX2017011732A (pt)
RU (1) RU2017132190A (pt)
WO (1) WO2016149643A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2017132190A (ru) * 2015-03-18 2019-04-18 Омнисайт Гибридные белки, содержащие модифицированные поверхностные гликопротеины альфавируса и опухолеассоциированный антиген, и способы, связанные с ними
US20200377598A1 (en) * 2017-03-03 2020-12-03 New York University Induction and Enhancement of Antitumor Immunity Involving Virus Vectors Expressing Multiple Epitopes of Tumor Associated Antigens and Immune Checkpoint Inhibitors or Proteins
CN110856724B (zh) * 2018-08-24 2022-05-27 杭州康万达医药科技有限公司 包含核酸及car修饰的免疫细胞的治疗剂及其应用
JP7457037B2 (ja) * 2019-05-31 2024-03-27 広州威溶特医薬科技有限公司 Ｍ１ウイルス変異体及びその使用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726288A (en) * 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
AU8762991A (en) * 1990-09-26 1992-04-15 Bristol-Myers Squibb Company Human papilloma viral protein expression for use in vaccine compositions
AUPN015794A0 (en) 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
ATE327259T1 (de) * 1997-08-05 2006-06-15 Stressgen Biotechnologies Corp Immunantwort gegen hpv antigene hervorgerufen von zusammensetzungen die ein hpv antigen und ein stressprotein enthalten oder einem expressionsvektor fähig zur expression dieser proteine
US6168932B1 (en) 1998-07-13 2001-01-02 Parker Hughes Institute Recombinant DTctGMCSF fusion toxin in a baculovirus expression vector system
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
ATE458059T1 (de) 2002-06-25 2010-03-15 Sekisui Chemical Co Ltd Expressionsvektor, wirt, fusionsprotein, verfahren zur herstellung von fusionsprotein und verfahren zur herstellung von protein
JP2005537800A (ja) 2002-09-06 2005-12-15 マンカインド コーポレイション エピトープ配列
US20080026077A1 (en) * 2002-11-12 2008-01-31 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
CN100528230C (zh) * 2003-02-19 2009-08-19 台桂香 重组人muc1-mbp融合蛋白抗肿瘤疫苗及生产工艺
WO2005087810A2 (en) * 2004-03-08 2005-09-22 Zymogenetics, Inc. Dimeric fusion proteins and materials and methods for producing them
CN100342017C (zh) * 2004-05-10 2007-10-10 中国医学科学院肿瘤医院肿瘤研究所 基因重组趋化抗原疫苗
EP1856250B1 (en) 2005-02-15 2013-07-24 The University of North Carolina At Chapel Hill New live virus vaccines
AU2006277295B2 (en) 2005-08-09 2011-08-11 Oncotherapy Science, Inc. Glypican-3 (GPC3)-derived tumor rejection antigenic peptides useful for HLA-A2-positive patients and pharmaceutical comprising the same
JP5137168B2 (ja) 2006-02-27 2013-02-06 独立行政法人科学技術振興機構 安定同位体標識脂肪族アミノ酸、その標的蛋白質への組み込み方法並びに蛋白質のｎｍｒ構造解析方法
DK2456786T4 (en) * 2009-07-24 2017-08-07 Immune Design Corp LENTIVIRUS VECTORS DETERMINED PSEUDOTYPE WITH A COAT PEGYCLOPROTEIN FROM SINDBIS VIRUS
TWI555531B (zh) 2009-08-07 2016-11-01 傳斯堅公司 用以治療ｂ型肝炎病毒（ｈｂｖ）感染之組成物
JP2014510721A (ja) * 2011-02-15 2014-05-01 イミューン デザイン コーポレイション ベクターワクチンによる免疫原特異的免疫応答を強化するための方法
MX350795B (es) * 2011-04-08 2017-09-19 Inmune Design Corp Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares.
US9637532B2 (en) * 2013-07-12 2017-05-02 Vlp Therapeutics, Llc Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
RU2017132190A (ru) * 2015-03-18 2019-04-18 Омнисайт Гибридные белки, содержащие модифицированные поверхностные гликопротеины альфавируса и опухолеассоциированный антиген, и способы, связанные с ними

Also Published As

Publication number Publication date
CN107530410B (zh) 2021-11-09
AU2016232771B2 (en) 2021-08-19
US20180243389A1 (en) 2018-08-30
CA2979697A1 (en) 2016-09-22
HK1248610A1 (zh) 2018-10-19
US20230181706A1 (en) 2023-06-15
RU2017132190A (ru) 2019-04-18
BR112017019776B1 (pt) 2020-07-28
JP6921053B2 (ja) 2021-08-18
CN107530410A (zh) 2018-01-02
AU2021269306A1 (en) 2021-12-09
EP3270958A2 (en) 2018-01-24
RU2017132190A3 (pt) 2019-08-30
WO2016149643A2 (en) 2016-09-22
AU2016232771A1 (en) 2017-10-05
MX2017011732A (es) 2018-08-15
EP3270958A4 (en) 2018-11-14
WO2016149643A3 (en) 2016-12-01
KR20170121301A (ko) 2017-11-01
CN114262380A (zh) 2022-04-01
US10660948B2 (en) 2020-05-26
JP2018509937A (ja) 2018-04-12
US20210077600A1 (en) 2021-03-18
US11471518B2 (en) 2022-10-18

Similar Documents

Publication Publication Date Title
CY1122790T1 (el) Αντι-ανθρωπινου ιου των θηλωματων 16 ε7 τ κυτταρου υποδοχεις
BR112019002687A2 (pt) receptores de antígeno quimérico que direcionam bcma e métodos de uso dos mesmos
CY1125392T1 (el) Συνθεσεις και μεθοδοι γλυζυλιωσης πρωτεϊνων
BR112019001737A2 (pt) expressão de pten-long com vírus oncolíticos
BR112017017293A2 (pt) método para predizer modificações de aminoácidos, para selecionar e/ou classificar modificações de aminoácidos e para fornecer uma vacina e vacina
BR112018071584A2 (pt) métodos para modular de maneira seletiva a ativida-de de subtipos distintos de células
BR112019000798A2 (pt) anticorpos contra o vírus zika e método de uso
BR112017019776A2 (pt) proteínas de fusão que compreendem glicoproteínas de superfície de alfavírus modificadas e antígeno associado a tumor e métodos dos mesmos
AU2016256582A8 (en) Oncolytic adenovirus encoding a B7 protein
EA202091513A1 (ru) Вакцины против вируса гепатита b (hbv) и их применение
BR112018017307A2 (pt) molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus
BR112018075032A2 (pt) proteínas de hemaglutinina do vírus influenza e seus uso
EA201400912A1 (ru) Рекомбинантные поксвирусные векторы, экспрессирующие белки вируса бешенства и ox40, и вакцины, созданные на их основе
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
EA201590829A1 (ru) Новые мукозные адъюванты и системы доставки
BR112017023131A2 (pt) anticorpos anti- fcrn
MX2019000215A (es) Composiciones inmunogenicas a base de listeria que comprenden antigenos de proteinas del tumor de wilms y metodos para su uso.
EA201892735A1 (ru) Состав вакцины против hiv
CY1124707T1 (el) Συνθεσεις και μεθοδοι για την επαγωγη ενισχυμενης ανοσοαποκρισης με χρηση φορεων ιων poxvirus (ευλογοϊων)
BR112021013507A2 (pt) Neoantígenos da próstata e seus usos
BR112018006006A2 (pt) receptores de antígeno, cadeias peptídicas, células recombinantes, métodos para produzir uma célula que expressa um receptor de antígeno e para o tratamento de uma doença, ácidos nucleicos e composição farmacêutica
WO2016191641A3 (en) Methods for enhancing antigen-specific immune responses using combination therapy comprising papillomavirus capsid antigens
WO2016116905A9 (en) Cmv antigens and uses thereof
BR112021022514A2 (pt) Conjugados de anticorpo e fármaco
BR112018073007A2 (pt) terapia de combinação inicial:reforço

Legal Events

Date Code Title Description
B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/03/2016, OBSERVADAS AS CONDICOES LEGAIS.